Singapore markets closed

Shin Kong Global Biotech & Health Care (0P00014ECY.TW)

Taiwan - Taiwan Delayed price. Currency in TWD
Add to watchlist
16.38+0.07 (+0.43%)
At close: 04:00AM CST

Shin Kong Global Biotech & Health Care

Taipei City 104, Taiwan (R.O.C.)

12F., No.123, Sec. 2, Nanjing E. Rd., Jhongshan District

(02)2507-1123
Management information
,Lead manager since 30 April 2024
學歷：馬里蘭大學企管所 經歷： 2002.08～2003.07 群益投顧研究部研究員 2003.07～2007.04 新光投信研究投資處研究員、吉富全球債券基金經理人 2007.10～2010.05 國泰人壽證券投資二部投資分析主任 2010.11～2011.05 兆豐國際投信國外投資部研究員 2011.05～迄今兆豐國際投信綠鑽基金經理人
Morningstar style box
Yahoo partners with Morningstar, a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box, which identifies a fund's investment focus, based on the underlying securities in the fund.
https://s.yimg.com/lq/i/fi/3_0stylelargeeq3.gif
Morningstar category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. Where necessary, we may change a category assignment based on recent changes to the portfolio.

Fund overview

CategoryN/A
Fund familyShin Kong Investment Trust Co Ltd
Net assetsN/A
YTD return4.24%
Yield0.00%
Morningstar rating★★★
Inception date1 Aug 2016

Fund operations

Last dividendN/A
Last cap gainN/A
Holdings turnoverN/A
Average for categoryN/A

Fees and expenses

Expense0P00014ECY.TWCategory average
Annual report expense ratio (net)0.00%N/A
Prospectus net expense ratio0.00%N/A
Prospectus gross expense ratio0.00%N/A
Max 12b1 feeN/AN/A
Max front end sales loadN/AN/A
Max deferred sales loadN/AN/A
3-yr expense projection0N/A
5-yr expense projection0N/A
10-yr expense projection0N/A